U.S. pharma big copyright scrapped two experimental weight loss capsules last calendar year—a the moment-daily pill, lotiglipron, resulting from elevated liver enzymes and also a 2 times-each day pill, danuglipron, as a consequence of robust side effects—but CEO Albert Bourla has explained the company is decided to “play and acquire” during